Home › Compare › SAEOF vs ABBV
SAEOF yields 55.56% · ABBV yields 3.09%● Live data
📍 SAEOF pulled ahead of the other in Year 1
Combined, SAEOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SAEOF + ABBV for your $10,000?
Sanden Corporation, together with its subsidiaries, manufactures and sells automotive equipment systems in Japan and internationally. It offers automotive air-conditioning systems, including system products, condensers, evaporators, heater cores, electric coolant heaters, pipes for air conditioning, and intercoolers, as well as heating, ventilating and air-conditioning units. The company also provides compressor products for automotive air conditioning, such as electric, swash plate and wobble plate type variable displacement, wobble and scroll plate type fixed displacement, and CO2 compressors. In addition, it provides living and environment systems. The company was formerly known as Sanden Holdings Corporation and changed its name to Sanden Corporation in January 2022. The company was founded in 1943 and is headquartered in Isesaki, Japan. Sanden Corporation is a subsidiary of Hisense Japan Automotive Air-Conditioning Systems Corporation.
Full SAEOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.